Relay Therapeutics (RLAY) Stock Price, News & Analysis

Company Overview

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for diseases driven by genetically defined targets, particularly in oncology. The company uses its proprietary Dynamo platform, which combines structural biology, computational modeling, machine learning and medicinal chemistry to study how proteins move and to identify potential drug-binding sites that may be difficult to address with conventional approaches.

Relay’s pipeline has included targeted cancer therapies such as RLY-2608, an investigational oral inhibitor designed to selectively target PI3K-alpha mutations, and RLY-4008 (lirafugratinib), an investigational FGFR2 inhibitor developed for cancers with specific FGFR2 alterations. The company evaluates its candidates through clinical studies and may pursue commercialization and development collaborations as programs advance.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Relay Therapeutics conducts research and clinical development activities intended to support the global treatment of cancer and other serious diseases. Sanjiv Patel serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $17.27 to $17.94
• 50-Day Range: $17.41 to $20.74
• 52-Week Range: $5.85 to $21.27
• Volume: 1.71 million shs
• Average Volume: 3.19 million shs
• Market Capitalization: $3.80 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.92
• Consensus Rating: Moderate Buy

Relay Therapeutics Stock Analysis - MarketRank™

Relay Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 573rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Relay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 2 strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Relay Therapeutics has a consensus price target of $25.92, representing about 49.0% upside from its current price of $17.39.

Amount of Analyst Coverage

Relay Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Relay Therapeutics are expected to decrease in the coming year, from ($1.61) to ($1.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Relay Therapeutics is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Relay Therapeutics is -11.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Relay Therapeutics has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.46% of the float of Relay Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Relay Therapeutics has a short interest ratio ("days to cover") of 12.59, which indicates bearish sentiment.

Change versus previous month

Short interest in Relay Therapeutics has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Relay Therapeutics does not currently pay a dividend.

Dividend Growth

Relay Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.66

News Sentiment

Relay Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Relay Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

7 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $119,185,022.00 in company stock.

Percentage Held by Insiders

5.04% of the stock of Relay Therapeutics is held by insiders.

Percentage Held by Institutions

96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RLAY
• CIK: 1812364
• Web: www.relaytx.com
• Phone: 617-370-8837
• Fax: N/A
• Employees: 192
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Relay Therapeutics: $25.92
• High Price Target: $31.00
• Low Price Target: $18.00
• Potential Upside/Downside: +49.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$276.48 million
• Net Margins: N/A
• Pretax Margin: -2,763.64%
• Return on Equity: -42.27%
• Return on Assets: -38.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.27
• Quick Ratio: 18.27

Sales & Book Value

• Annual Sales: $15.35 million
• Price / Sales: 247.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.27 per share
• Price / Book: 5.31

Miscellaneous

• Outstanding Shares: 219,140,000
• Free Float: 208,097,000
• Market Cap: $3.80 billion
• Optionable: Optionable
• Beta: 1.72